Research

Hormonal

Tirzepatide treatment in people with type 2 diabetes shifts body fat distribution toward a more balanced pattern by significantly reducing visceral adipose tissue (VAT) and liver fat (LF) while preserving abdominal subcutaneous adipose tissue (aSAT) relative to the amount of weight lost.

If you have type 2 diabetes and are prescribed tirzepatide, expect significant reductions in dangerous visceral and liver fat. Importantly, the drug appears to preserve your subcutaneous fat (the fat under the skin) better than other weight-loss methods might, leading to a healthier overall fat distribution pattern. This shift occurs alongside weight loss and improves cardiometabolic risk markers.

GoodSupportsHIGH confidence
In this exploratory analysis, treatment with tirzepatide in people with T2D resulted in a significant reduction of z-VAT and z-LF, while z-aSAT was increased from an initially negative value, suggesting a possible treatment-related shift towards a more balanced fat distribution pattern with prominent VAT and LF loss.
Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2024

Why this rating

Randomized controlled trial (SURPASS-3) with MRI-measured outcomes and virtual control groups, though the fat distribution analysis is exploratory.

Source

Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes

Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2024

DOI 10.1111/dom.15566

rct · n=296Cited 27×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →